Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are REGN, LLY, BSX, MDT, ISRG, and represent 17.71% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: REGN (+$20M), VERA (+$15M), AMGN (+$12M), NUVL (+$11M), DOCS (+$11M), PNTG (+$10M), ARWR (+$9.6M), MDT (+$8.7M), IDYA (+$8.6M), LIVN (+$8.4M).
- Started 13 new stock positions in OSCR, WST, ASND, AMGN, STE, CRL, QURE, PNTG, ARWR, IDYA. A, BBIO, CNTA.
- Reduced shares in these 10 stocks: , , CYTK (-$13M), ABT (-$13M), LLY (-$12M), IONS (-$12M), AKRO (-$11M), AXSM (-$11M), ALHC (-$9.3M), DHR (-$8.1M).
- Sold out of its positions in ABT, AKRO, ANNX, TECH, CAH, DVAX, EXAS, RARE, UTHR, UHS. MRUS.
- Rhenman & Partners Asset Management AB was a net buyer of stock by $49M.
- Rhenman & Partners Asset Management AB has $1.1B in assets under management (AUM), dropping by 18.41%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 94 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals (REGN) | 4.4 | $47M | +70% | 61k | 771.87 |
|
| Eli Lilly & Co. (LLY) | 4.2 | $45M | -20% | 42k | 1074.68 |
|
| Boston Scientific Corporation (BSX) | 3.8 | $41M | 431k | 95.35 |
|
|
| Medtronic SHS (MDT) | 2.7 | $28M | +44% | 296k | 96.06 |
|
| Intuitive Surgical Com New (ISRG) | 2.5 | $27M | 48k | 566.36 |
|
|
| Cooper Cos (COO) | 2.5 | $27M | +38% | 328k | 81.96 |
|
| CVS Caremark Corporation (CVS) | 2.5 | $27M | +20% | 336k | 79.36 |
|
| Abbvie (ABBV) | 2.4 | $25M | -15% | 111k | 228.49 |
|
| Glaukos (GKOS) | 2.2 | $24M | -8% | 210k | 112.91 |
|
| Danaher Corporation (DHR) | 2.1 | $23M | -26% | 99k | 228.92 |
|
| AmerisourceBergen (COR) | 2.0 | $21M | 63k | 337.75 |
|
|
| Vera Therapeutics Cl A (VERA) | 2.0 | $21M | +223% | 420k | 50.64 |
|
| McKesson Corporation (MCK) | 2.0 | $21M | -3% | 26k | 820.29 |
|
| Axsome Therapeutics (AXSM) | 2.0 | $21M | -33% | 115k | 182.64 |
|
| Alignment Healthcare (ALHC) | 1.9 | $20M | -31% | 1.0M | 19.75 |
|
| Insmed Com Par $.01 (INSM) | 1.8 | $20M | -13% | 114k | 174.04 |
|
| Thermo Fisher Scientific (TMO) | 1.8 | $20M | +11% | 34k | 579.45 |
|
| Procept Biorobotics Corp (PRCT) | 1.8 | $19M | +56% | 611k | 31.46 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.7 | $18M | +43% | 46k | 397.65 |
|
| UnitedHealth (UNH) | 1.7 | $18M | -12% | 55k | 330.11 |
|
| Neurocrine Biosciences (NBIX) | 1.7 | $18M | +9% | 126k | 141.83 |
|
| Insulet Corporation (PODD) | 1.6 | $17M | +5% | 61k | 284.24 |
|
| Doximity Cl A (DOCS) | 1.5 | $17M | +174% | 373k | 44.28 |
|
| Edwards Lifesciences (EW) | 1.5 | $17M | +24% | 194k | 85.25 |
|
| Nuvalent Inc-a (NUVL) | 1.5 | $16M | +211% | 163k | 100.59 |
|
| Biogen Idec (BIIB) | 1.5 | $16M | +67% | 92k | 175.99 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.5 | $16M | -27% | 34k | 453.36 |
|
| Encompass Health Corp (EHC) | 1.5 | $16M | +22% | 146k | 106.14 |
|
| Gilead Sciences (GILD) | 1.4 | $16M | +57% | 126k | 122.74 |
|
| Align Technology (ALGN) | 1.4 | $16M | +19% | 99k | 156.15 |
|
| Tenet Healthcare Corp Com New (THC) | 1.4 | $15M | +30% | 77k | 198.72 |
|
| BioMarin Pharmaceutical (BMRN) | 1.2 | $13M | +15% | 215k | 59.43 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.2 | $13M | -22% | 74k | 170.00 |
|
| Ionis Pharmaceuticals (IONS) | 1.2 | $13M | -48% | 159k | 79.11 |
|
| Amgen (AMGN) | 1.1 | $12M | NEW | 36k | 327.31 |
|
| Livanova SHS (LIVN) | 1.1 | $12M | +258% | 190k | 61.53 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.1 | $11M | +7% | 20k | 582.34 |
|
| Cigna Corp (CI) | 1.0 | $11M | -16% | 39k | 275.23 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.0 | $10M | -18% | 148k | 69.55 |
|
| Syndax Pharmaceuticals (SNDX) | 1.0 | $10M | -15% | 487k | 21.01 |
|
| Nurix Therapeutics (NRIX) | 1.0 | $10M | +54% | 538k | 18.97 |
|
| Pennant Group (PNTG) | 0.9 | $10M | NEW | 357k | 28.15 |
|
| Adaptive Biotechnologies Cor (ADPT) | 0.9 | $9.8M | +22% | 605k | 16.24 |
|
| Penumbra (PEN) | 0.9 | $9.8M | +53% | 32k | 310.91 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.9 | $9.6M | NEW | 145k | 66.39 |
|
| Apellis Pharmaceuticals (APLS) | 0.9 | $9.4M | +61% | 375k | 25.12 |
|
| Natera (NTRA) | 0.9 | $9.3M | +30% | 41k | 229.09 |
|
| Kura Oncology (KURA) | 0.8 | $9.1M | +77% | 872k | 10.39 |
|
| Arcellx Common Stock (ACLX) | 0.8 | $8.7M | +104% | 134k | 65.20 |
|
| Ideaya Biosciences (IDYA) | 0.8 | $8.6M | NEW | 250k | 34.57 |
|
| Mirum Pharmaceuticals (MIRM) | 0.8 | $8.4M | +88% | 106k | 78.99 |
|
| Guardant Health (GH) | 0.8 | $8.2M | +60% | 80k | 102.14 |
|
| Royalty Pharma Shs Class A (RPRX) | 0.7 | $8.0M | -20% | 207k | 38.64 |
|
| Brightspring Health Svcs (BTSG) | 0.7 | $7.4M | +230% | 198k | 37.45 |
|
| Bruker Corporation (BRKR) | 0.6 | $6.9M | -4% | 147k | 47.11 |
|
| Stoke Therapeutics (STOK) | 0.6 | $6.9M | -13% | 216k | 31.74 |
|
| Bridgebio Pharma (BBIO) | 0.6 | $6.2M | NEW | 82k | 76.49 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $6.2M | +71% | 139k | 44.82 |
|
| Anteris Technologies Global (AVR) | 0.6 | $6.2M | 1.2M | 4.99 |
|
|
| Krystal Biotech (KRYS) | 0.6 | $6.2M | +112% | 25k | 246.54 |
|
| Iqvia Holdings (IQV) | 0.6 | $6.0M | +35% | 27k | 225.41 |
|
| Immunocore Hldgs Ads (IMCR) | 0.5 | $5.3M | +442% | 153k | 34.71 |
|
| Anthem (ELV) | 0.5 | $5.3M | -33% | 15k | 350.55 |
|
| Mineralys Therapeutics (MLYS) | 0.5 | $5.2M | -13% | 143k | 36.29 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.4 | $4.8M | +75% | 364k | 13.18 |
|
| Charles River Laboratories (CRL) | 0.4 | $4.4M | NEW | 22k | 199.48 |
|
| Iovance Biotherapeutics (IOVA) | 0.4 | $4.4M | +45% | 1.6M | 2.73 |
|
| Vericel (VCEL) | 0.4 | $4.2M | 117k | 36.01 |
|
|
| Dianthus Therapeutics (DNTH) | 0.4 | $4.1M | -43% | 99k | 41.21 |
|
| Relay Therapeutics (RLAY) | 0.4 | $3.9M | 460k | 8.46 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.4 | $3.7M | 35k | 107.04 |
|
|
| Oscar Health Cl A (OSCR) | 0.3 | $3.7M | NEW | 260k | 14.37 |
|
| Alkermes SHS (ALKS) | 0.3 | $3.7M | +41% | 133k | 27.98 |
|
| RadNet (RDNT) | 0.3 | $3.4M | -6% | 47k | 71.35 |
|
| Inspire Med Sys (INSP) | 0.3 | $3.3M | -41% | 36k | 92.23 |
|
| Ocular Therapeutix (OCUL) | 0.3 | $3.2M | +31% | 265k | 12.14 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.3 | $3.2M | NEW | 15k | 213.24 |
|
| Janux Therapeutics (JANX) | 0.3 | $3.1M | +125% | 225k | 13.80 |
|
| Privia Health Group (PRVA) | 0.3 | $3.0M | -35% | 125k | 23.71 |
|
| Stevanato Group S P A Ord Srs (STVN) | 0.3 | $3.0M | +188% | 147k | 20.12 |
|
| Viking Therapeutics (VKTX) | 0.3 | $2.9M | -61% | 83k | 35.18 |
|
| Cytokinetics Com New (CYTK) | 0.3 | $2.8M | -82% | 44k | 63.54 |
|
| Agilent Technologies Inc C ommon (A) | 0.3 | $2.7M | NEW | 20k | 136.07 |
|
| Xencor (XNCR) | 0.2 | $2.5M | 166k | 15.31 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $2.5M | NEW | 100k | 25.01 |
|
| Tg Therapeutics (TGTX) | 0.2 | $2.2M | -21% | 73k | 29.81 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.2 | $2.0M | -41% | 21k | 95.20 |
|
| West Pharmaceutical Services (WST) | 0.2 | $1.9M | NEW | 7.0k | 275.14 |
|
| Centene Corporation (CNC) | 0.2 | $1.9M | -72% | 46k | 41.15 |
|
| Uniqure Nv SHS (QURE) | 0.2 | $1.9M | NEW | 79k | 23.93 |
|
| Denali Therapeutics (DNLI) | 0.2 | $1.7M | 100k | 16.51 |
|
|
| Steris Shs Usd (STE) | 0.1 | $1.5M | NEW | 6.0k | 253.52 |
|
| Irhythm Technologies (IRTC) | 0.1 | $1.2M | 7.0k | 177.44 |
|
|
| Alphatec Hldgs Com New (ATEC) | 0.0 | $421k | +11% | 20k | 21.04 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2025 Q4 filed Feb. 13, 2026
- Rhenman & Partners Asset Management AB 2025 Q3 filed Nov. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q2 filed Aug. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q1 filed May 14, 2025
- Rhenman & Partners Asset Management AB 2024 Q4 filed Feb. 13, 2025
- Rhenman & Partners Asset Management AB 2024 Q3 filed Nov. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q2 filed Aug. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q1 filed May 14, 2024
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022
- Rhenman & Partners Asset Management AB 2022 Q2 filed Aug. 12, 2022
- Rhenman & Partners Asset Management AB 2022 Q1 filed May 13, 2022